Immune-mediated necrotizing myopathy;Immunvermittelte nekrotisierende Myopathie

Zeitschrift fur Rheumatologie

Volumn 75, Issue 2, 2016, Pages 151-156

  Bergua, C ^a,b   Chiavelli, H ^a,b   Simon, J P ^c   Boyer, O ^a,b,d   Jouen, F ^a,d   Stenzel, W ^e   Martinet, J ^a,b,d  

^a UNIVERSITY OF ROUEN   (France)

^b INSERM   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Autoantibodies; Autoimmune disease; Myositis; Pathophysiology; Statins

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; MYOSITIS; NONHUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); AUTOIMMUNE DISEASES; EVIDENCE BASED MEDICINE; GERMANY; PREVALENCE; RARE DISEASES; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; EVIDENCE-BASED MEDICINE; GERMANY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOSITIS; PREVALENCE; RARE DISEASES; TREATMENT OUTCOME;

EID: 84961201540     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-015-0029-3     Document Type: Article

References (38)

1. Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372:1734–1747
2. Hoogendijk JE et al (2004) 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14:337–345
3. Christopher-Stine L et al (2010) A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62:2757–2766
4. Hengstman GJD et al (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65:1635–1638
5. Liang C, Needham M (2011) Necrotizing autoimmune myopathy. Curr Opin Rheumatol 23:612–619
6. Reeves WH, Nigam SK, Blobel G (1986) Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A 83:9507–9511
7. Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am 28:723–741
8. Rouster-Stevens KA, Pachman LM (2008) Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol 35:927–929
9. Alshehri A, Choksi R, Bucelli R, Pestronk A (2015) Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2:e124
10. Drouot L et al (2014) Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther 16:R39
11. Miller T, Al-Lozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 73:420–428
12. Allenbach Y et al (2014) Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 93:150–157
13. Mammen AL et al (2012) Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res 64:1233–1237
14. Mammen AL et al (2011) Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63:713–721
15. Werner JL et al (2012) Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 64:4087–4093
16. Limaye V et al (2014) Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy. Muscle Nerve 52(2):196–203. doi:10.1002/mus.24541
17. Watanabe Y et al (2015) Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore) 94:e416
18. Mammen AL et al (2012) Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res 64:269–272
19. Chung T, Christopher-Stine L, Paik JJ, Corse A, Mammen AL (2015) The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve 52(2):189–195. doi:10.1002/mus.24642
20. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV (2004) Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50:209–215
21. Römisch K, Miller FW, Dobberstein B, High S (2006) Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 8:R39
22. Bronner IM et al (2003) Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 250:480–485
23. Iaccarino L et al (2014) Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation. Auto Immun Highlights 5:87–94
24. Benveniste O et al (2011) Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 63:1961–1971
25. Targoff IN, Johnson AE, Miller FW (1990) Antibody to signal recognition particle in polymyositis. Arthritis Rheum 33:1361–1370
26. Claeys KG et al (2013) Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. Neurology 81:932–935
27. Aouizerate J et al (2014) Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathol Commun 2:154
28. Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367–371
29. Mescam-Mancini L et al (2015) Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain J Neurol 138:2485–2492
30. Stenzel W et al (2015) Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 84:1346–1354
31. Chatterjee S (2013) Antisynthetase syndrome: Not just an inflammatory myopathy. Cleve Clin J Med 80(10):655–666
32. Smith B (1969) Skeletal muscle necrosis associated with carcinoma. J Pathol 97:207–210
33. Wegener S, Bremer J, Komminoth P, Jung HH, Weller M (2010) Paraneoplastic Necrotizing Myopathy with a mild inflammatory component: a case report and review of the literature. Case Rep Oncol 3(1):88–92
34. Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M (2015) Clinical features and treatment outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurol 72(9):996–1003. doi:10.1001/jamaneurol.2015.1207
35. Dalakas MC (2010) Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 6:129–137
36. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62:1328–1334
37. Curtin D et al (2014) Novel antibody associations in immune-mediated necrotising myopathy without inflammation. Ir J Med Sci. doi:10.1007/s11845-014-1207-z
38. Grable-Esposito P et al (2010) Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41:185–190